- Home
- NSTS vs INZY Comparison
NSTS vs INZY Comparison
Compare NSTS & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- INZY
- Stock Information
- Founded
- NSTS 1921
- INZY 2015
- Country
- NSTS United States
- INZY United States
- Employees
- NSTS N/A
- INZY N/A
- Industry
- NSTS Savings Institutions
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- INZY Health Care
- Exchange
- NSTS Nasdaq
- INZY Nasdaq
- Market Cap
- NSTS 65.8M
- INZY 64.9M
- IPO Year
- NSTS N/A
- INZY 2020
- Fundamental
- Price
- NSTS N/A
- INZY $0.92
- Analyst Decision
- NSTS
- INZY Strong Buy
- Analyst Count
- NSTS 0
- INZY 9
- Target Price
- NSTS N/A
- INZY $17.22
- AVG Volume (30 Days)
- NSTS 2.7K
- INZY 453.8K
- Earning Date
- NSTS 05-12-2025
- INZY 05-06-2025
- Dividend Yield
- NSTS N/A
- INZY N/A
- EPS Growth
- NSTS N/A
- INZY N/A
- EPS
- NSTS N/A
- INZY N/A
- Revenue
- NSTS $8,931,000.00
- INZY N/A
- Revenue This Year
- NSTS N/A
- INZY N/A
- Revenue Next Year
- NSTS N/A
- INZY N/A
- P/E Ratio
- NSTS N/A
- INZY N/A
- Revenue Growth
- NSTS 82.49
- INZY N/A
- 52 Week Low
- NSTS $9.37
- INZY $0.72
- 52 Week High
- NSTS $13.32
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- NSTS 60.88
- INZY 44.29
- Support Level
- NSTS $10.80
- INZY $0.83
- Resistance Level
- NSTS $12.22
- INZY $1.08
- Average True Range (ATR)
- NSTS 0.26
- INZY 0.11
- MACD
- NSTS 0.12
- INZY 0.02
- Stochastic Oscillator
- NSTS 98.45
- INZY 55.43
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.